Clinical trial NCT00736086: RISE: A Clinical Evaluation of the StarClose™ Vascular Closure System
Official title: A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Peripheral Vascular Disease
Cardiovascular Disease
Keywords: femoral artery
post-percutaneous cardiac catheterization
post-percutaneous peripheral vascular catheterization
post-percutaneous diagnostic catheterization
early ambulation
vascular closure
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2008-08-15
Enrollment: 165
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects who are ambulated early post-percutaneous, cardiac or peripheral vascular, diagnostic catheterization procedure

Brief summary: To evaluate early ambulation in patients who receive the StarClose™ VCS post-percutaneous diagnostic procedure.

Detailed description: To evaluate the StarClose™ VCS in the femoral artery in subjects who are ambulated early post-percutaneous cardiac or peripheral vascular, diagnostic catheterization procedure. The clinical use of vascular closure devices for rapid hemostasis after femoral access was first reported in 1991. 18 participants may be ambulated almost immediately after diagnostic coronary angiography and discharged many hours earlier than currently practiced in most centers utilizing a supine restriction period of 6 hours after diagnostic catheterization.14 After coronary interventions, participant comfort is additionally increased by immediate sheath removal.

This early ambulation study is an evaluation of a clip-based technology, which achieves vascular hemostasis with the use of a novel extravascular Nitinol clip to provide an immediate mechanical closure that does not depend upon the body's clotting system. The procedures will be performed in participants who meet specific entrance criteria.

Eligibility criteria: Inclusion:

* Subject must be 18-85.
* Subject must be an acceptable candidate for an elective,non-emergent diagnostic procedure performed percutaneously via the common femoral artery through either a 5F or 6F procedural sheath.
* Subject is an acceptable candidate for emergent vascular surgery.
* Subject agrees to follow-up evaluations to assess for complications related to femoral access site.
* If among the 50 ultrasound sub-study Subjects enrolled,Subject agrees to have an ultrasound of femoral artery performed post-procedure during the 30 ± 7 days follow-up visit.
* Subject or legal representative has been informed of the nature of the study and agrees to provisions and has provided written informed consent as approved by the Institutional Review Board of respective clinical site.

Exclusion:

* History of bleeding diathesis or coagulopathy including hemophilia, von Willebrand's disease, and/or a current, known platelet count \<100,000 cells/mm3, or baseline INR \> 1.7.
* Body Mass Index (BMI) ³ 35 kg/m2.
* Presence of significant anemia (Hgb \< 10 g/dL, Hct \< 30%).
* Advanced Subject refusal of blood transfusions, should transfusion become necessary.
* Participation in another trial of an investigational drug or device that has not yet completed follow-up requirements.
* Pregnant or lactating female.
* Clinically severe peripheral vascular disease in the ipsilateral limb, defined as severe claudication (walking \< 100 feet), weak or absent pulses, or lower extremity vascular graft.
* History of ipsilateral femoral arterial puncture within previous three months or history of vascular closure device deployment in ipsilateral femoral artery at any time.
* Subject has unilateral or bilateral lower extremity amputation(s).
* Subject is unable to routinely walk at least 20 feet without assistance.
* Subject has an active systemic or cutaneous infection or inflammation.
* Subject has a pre-existing severe non-cardiac systemic disease or illness with a life expectancy of \< 30 days.
* Subject has already participated in this Study.
* Subject has known allergy to nitinol.

Access Site Exclusion-(\*Evaluated via Limited Femoral Angiogram)

* Pseudoaneurysm or AV fistula present in ipsilateral femoral artery prior to arterial closure.\*
* Puncture distal to the common femoral artery bifurcation or above the inguinal ligament which is typically defined by the inferior border of the inferior epigastric artery on sheath angiogram or the upper third of the femoral head by plain fluoroscopy.\*
* The arterial lumen diameter at the arteriotomy site is \< 5mm by visual estimate.\*
* Angiographic evidence of calcified lesions at the arteriotomy site.\*
* Difficulty inserting the introducer sheath at the start of the catheterization procedure due to vessel scarring or tortuosity, or anterior/posterior wall femoral artery punctures or greater than 2 ipsilateral arterial puncture attempts at the time of the percutaneous procedure.
* Known iliac or femoral stenosis \>50% or previous bypass surgery or stent placement in the vicinity of the puncture site.
* Planned percutaneous procedure (diagnostic or intervention) in ipsilateral femoral artery prior to the 30-day follow-up evaluation.
* Subject has intra-procedural bleeding around the access site.
* Presence or previous use of an intra-aortic balloon pump through the existing arterial puncture site.

Procedural Exclusion:

* Low molecular weight heparin administration within 8 hours of enrollment.
* For cases where anticoagulants are used, ACT level \> 350 seconds at time of enrollment.
* Subject is determined to require treatment that will extend hospitalization (e.g. ---Subject is undergoing CABG surgery or staged PTCA).
* Persistent hypertension (SBP \>180 or DBP \>110 mm Hg) unresponsive to medical -therapy at time of enrollment.
* Placement of an ipsilateral femoral venous sheath during procedure.
* Presence of clinically significant hematoma (\> 6 cm) in ipsilateral femoral artery prior to arterial closure.
* Placement of introducer sheath \< 5F or \> 6F during procedure.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Scripps Memorial Hospital
state: California
city: Atlanta
country: United States
facility: Fuqua Heart Center/ Piedmont Hospital
state: Georgia
city: Peoria
country: United States
facility: Heart Care Midwest (OSF/St Francis)
state: Illinois
city: Indianapolis
country: United States
facility: The Care Group LLC (St. Vincent's Hospital)
state: Indiana
city: Bay City
country: United States
facility: Bay Regional Medical Center
state: Michigan
city: Minneapolis
country: United States
facility: Minneapolis Heart Institute Foundation/Abbott Northwestern Hospital
state: Minnesota
city: Kansas City
country: United States
facility: St. Luke's Hospital
state: Missouri
city: Brooklyn
country: United States
facility: New York Methodist Hospital
state: New York
city: Buffalo
country: United States
facility: Buffalo Heart group
state: New York
city: Elyria
country: United States
facility: North Ohio Research LTD Elyria Regional Medical
state: Ohio
city: Philadelphia
country: United States
facility: Drexel University College of Medicine Hahnemann
state: Pennsylvania
Study officials:
affiliation: Drexel University/Hahnemann
name: William Kussmaul, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Krone RJ, Johnson L, Noto T. Five year trends in cardiac catheterization: a report from the Registry of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn. 1996 Sep;39(1):31-5. doi: 10.1002/ccd.1810390102.
citation: Waksman R, Scott NA, Ghazzal ZM, Mays R, Frerichs FA, Petersen JY, King SB 3rd. Randomized comparison of flexible versus nonflexible femoral sheaths on patient comfort after angioplasty. Am Heart J. 1996 Jun;131(6):1076-8. doi: 10.1016/s0002-8703(96)90079-4.
citation: Bogart DB, Bogart MA, Miller JT, Farrar MW, Barr WK, Montgomery MA. Femoral artery catheterization complications: a study of 503 consecutive patients. Cathet Cardiovasc Diagn. 1995 Jan;34(1):8-13. doi: 10.1002/ccd.1810340304.
citation: Christensen B, Lacarella C, Manion R, Bruhn-Ding B, Meyer S, Wilson R. Sandbags do not prevent complications after catheterization. Circulation 90:I-205, 1994.
citation: Pracyk JB, Wall TC, Longabaugh JP, Tice FD, Hochrein J, Green C, Cox G, Lee K, Stack RS, Tcheng JE. A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention. Am J Cardiol. 1998 Apr 15;81(8):970-6. doi: 10.1016/s0002-9149(98)00074-5.
citation: Resar JR, Prewitt KC, Wolff MR, Blumenthal R, Raqueno JV, Brinker JA. Percutaneous transluminal coronary angioplasty through 6F diagnostic catheters: a feasibility study. Am Heart J. 1993 Jun;125(6):1591-6. doi: 10.1016/0002-8703(93)90745-u.
citation: Cragg AH, Nakagawa N, Smith TP, Berbaum KS. Hematoma formation after diagnostic angiography: effect of catheter size. J Vasc Interv Radiol. 1991 May;2(2):231-3. doi: 10.1016/s1051-0443(91)72287-2.
citation: Waksman R, King SB 3rd, Douglas JS, Shen Y, Ewing H, Mueller L, Ghazzal ZM, Weintraub WS. Predictors of groin complications after balloon and new-device coronary intervention. Am J Cardiol. 1995 May 1;75(14):886-9. doi: 10.1016/s0002-9149(99)80681-x.
citation: Campeau L. Percutaneous radial artery approach for coronary angiography. Cathet Cardiovasc Diagn. 1989 Jan;16(1):3-7. doi: 10.1002/ccd.1810160103.
citation: Kiemeneij F, Laarman GJ, Odekerken D, Slagboom T, van der Wieken R. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. J Am Coll Cardiol. 1997 May;29(6):1269-75. doi: 10.1016/s0735-1097(97)00064-8.
citation: Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation. 1998 Oct 20;98(16):1597-603. doi: 10.1161/01.cir.98.16.1597.
citation: Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998 Dec 3;339(23):1665-71. doi: 10.1056/NEJM199812033392303.
citation: Dick RJ, Popma JJ, Muller DW, Burek KA, Topol EJ. In-hospital costs associated with new percutaneous coronary devices. Am J Cardiol. 1991 Oct 1;68(9):879-85. doi: 10.1016/0002-9149(91)90403-8.
citation: Krause PB, Klein LW. Utility of a percutaneous collagen hemostasis device: to plug or not to plug? J Am Coll Cardiol. 1993 Nov 1;22(5):1280-2. doi: 10.1016/0735-1097(93)90530-e. No abstract available.
citation: Anderson HV, Bertrand M, Whitworth HB, Sax FL, Willerson JT for the Restore Investigators. Bleeding risk with platelet inhibition using Tirofiban: The Restore Trial. Circulation. 94:I-553, 1996.
citation: Lincoff AM, Tcheng JE, Miller DP, Booth JE, Montague EA, Topol EJ. Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3Fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials. Circulation 94:I-375, 1996.
citation: Goods CM, Liu MW, Jain SP, Mathur A, Yadav JS, Al-Shalbi KF, Dean LS, Iyer SS, Parks JM, Roubin GS. Low molecular weight heparin versus standard heparin in participants at high risk for stent thrombosis: Clinical outcomes. Circulation 94:I-684, 1996.
citation: Ernst S, Kloss R, Schräder R, Kaltenbach M, Sigwart U, Sanborn TA. Immediate sealing of arterial puncture sites after catheterization and PTCA using a vascular hemostasis device with collagen: an international study. Circulation 84:I-272, 1991.
citation: Silber S, Dorr R, Muhling H, Konig U. Sheath pulling immediately after PTCA: comparison of two different deployment techniques for the hemostatic puncture closure device: a prospective, randomized study. Cathet Cardiovasc Diagn. 1997 Aug;41(4):378-83. doi: 10.1002/(sici)1097-0304(199708)41:43.0.co;2-2.
citation: Silber S. Rapid hemostasis of arterial puncture sites with collagen in patients undergoing diagnostic and interventional cardiac catheterization. Clin Cardiol. 1997 Dec;20(12):981-92. doi: 10.1002/clc.4960201203.
citation: Silber S. Hemostasis success rates and local complications with collagen after femoral access for cardiac catheterization: analysis of 6007 published patients. Am Heart J. 1998 Jan;135(1):152-6. doi: 10.1016/s0002-8703(98)70356-4.
citation: Hoffer EK, Bloch RD. Percutaneous arterial closure devices. J Vasc Interv Radiol. 2003 Jul;14(7):865-85. doi: 10.1097/01.rvi.0000071086.76348.8e.
citation: Duffin DC, Muhlestein JB, Allisson SB, Horne BD, Fowles RE, Sorensen SG, Revenaugh JR, Bair TL, Lappe DL. Femoral arterial puncture management after percutaneous coronary procedures: a comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices. J Invasive Cardiol. 2001 May;13(5):354-62.
citation: Shammas NW, Rajendran VR, Alldredge SG, Witcik WJ, Robken JA, Lewis JR, McKinney D, Hansen CA, Kabel ME, Harris M, Jerin MJ, Bontu PR, Dippel EJ, Labroo A. Randomized comparison of Vasoseal and Angioseal closure devices in patients undergoing coronary angiography and angioplasty. Catheter Cardiovasc Interv. 2002 Apr;55(4):421-5. doi: 10.1002/ccd.10098.
citation: Ward SR, Casale P, Raymond R, Kussmaul WG 3rd, Simpfendorfer C. Efficacy and safety of a hemostatic puncture closure device with early ambulation after coronary angiography. Angio-Seal Investigators. Am J Cardiol. 1998 Mar 1;81(5):569-72. doi: 10.1016/s0002-9149(97)00970-3.
citation: Kussmaul WG 3rd, Buchbinder M, Whitlow PL, Aker UT, Heuser RR, King SB, Kent KM, Leon MB, Kolansky DM, Sandza JG Jr. Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol. 1995 Jun;25(7):1685-92. doi: 10.1016/0735-1097(95)00101-9.
citation: Kapadia SR, Raymond R, Knopf W, Jenkins S, Chapekis A, Ansel G, Rothbaum D, Kussmaul W, Teirstein P, Reisman M, Casale P, Oster L, Simpfendorfer C. The 6Fr Angio-Seal arterial closure device: results from a multimember prospective registry. Am J Cardiol. 2001 Mar 15;87(6):789-91, A8. doi: 10.1016/s0002-9149(00)01507-1.
citation: Burke MN, Hermiller J, Jaff MR. StarClose vascular closure system (VCS) is safe and effective in patients who ambulate early following successful femoral artery access closure--results from the RISE clinical trial. Catheter Cardiovasc Interv. 2012 Jul 1;80(1):45-52. doi: 10.1002/ccd.23176. Epub 2011 Dec 8.